Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Beeline Medicines debuts with $300M Series A

Lucid Diligence Brief: Beeline Medicines debuts with $300M Series A…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Eli Lilly acquires Centessa Pharmaceuticals

Lucid Diligence Brief: Eli Lilly acquires Centessa Pharmaceuticals Professional…


ACC 2026 Preview

ACC 2026 Preview: Key Cardiology Highlights to Watch

ACC 2026 at a Glance Get ready for ACC 2026. LucidQuest’s preview highlights…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D deal for JNJ-4804

Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Otsuka to acquire Transcend Therapeutics

Lucid Diligence Brief: Otsuka to acquire Transcend Therapeutics Professional…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: AstraZeneca's tozorakimab meets primary endpoint in COPD

Lucid Diligence Brief: AstraZeneca's tozorakimab meets primary endpoint in……


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Pinnacle Medicines $89 million Series B

Lucid Diligence Brief: Pinnacle Medicines $89 million Series B Professional…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: MSD to acquire Terns

Lucid Diligence Brief: MSD to acquire Terns Professional audiences only. Not…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Gilead Sciences to acquire Ouro Medicines

Lucid Diligence Brief: Gilead Sciences to acquire Ouro Medicines Professional…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Novartis to acquire Pikavation Therapeutics from Synnovation

Lucid Diligence Brief: Novartis to acquire Pikavation Therapeutics from…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Kupando adds €10 million to its Series A for Toll-like receptor assets

Lucid Diligence Brief: Kupando adds €10 million to its Series A for Toll-like…


Privacy Preference Center